Biocytogen’s Post

✨ Get ready for #AETEU 2026 in Basel, Switzerland! 🗣 Join us for our Oral Presentation to learn more about our First-in-Class Asset— BCG048, a Novel Bispecific Dual-payload ADC Targeting ITGB6 and B7H3, Exhibited Potent Efficacy in Patient-derived Tumor Xenograft Models. ⏰ May 29 | 10:00–10:15 AM 🎤 Guoli Zheng, Associate Director, Business Development - Licensing 📃 We will also be presenting posters on Poster Board 38  ⏰ Poster Viewing Hours: • May 27: 6:45 AM–6:45 PM • May 28: 7:15 AM–5:55 PM • May 29: 8:00 AM–3:45 PM Stop by Booth 22 during networking breaks and lunch to learn more and connect with our team. We look forward to seeing you in Basel! #Biocytogen #AETEurope #AntibodyTherapeutics #ADC #BispecificAntibodies #Oncology